Compounds > pyrroles
Page last updated: 2024-08-18

pyrroles and Myelodysplastic Syndromes

pyrroles has been researched along with Myelodysplastic Syndromes in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Asatiani, E; Berenson, JR; Bordoni, R; Cook, RJ; Edenfield, WJ; Mohan, S; Savona, MR; Srinivas, N; Zeidan, AM; Zhou, G1
Battista, K; Buckstein, R; Howson-Jan, K; Ivy, SP; Kovacs, MJ; Oza, AM; Schuh, AC; Storring, JM; Wang, ES; Wang, L; Wells, RA; Xenocostas, A; Yee, KW1
Arellano, ML; Berger, M; Borthakur, G; Luer, J; Raza, A1
Albitar, M; Cherrington, JM; Cooper, MA; Cortes, JE; Giles, FJ; Hannah, AL; Hong, W; Kantarjian, HM; Karp, JE; Lancet, JE; Louie, SG; O'Brien, SM; O'Farrell, AM; Silverman, LR; Stopeck, AT; Verstovsek, S; Yuen, HA1
Grosicka, A; Grosicki, S; HoĊ‚owiecki, J1

Reviews

1 review(s) available for pyrroles and Myelodysplastic Syndromes

ArticleYear
[Clinical importance of angiogenesis and angiogenic factors in oncohematology].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2007, Volume: 60, Issue:1-2

    Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Angiopoietin-1; Angiopoietin-2; Hematologic Neoplasms; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Metastasis; Neovascularization, Pathologic; Oxindoles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Propionates; Pyrroles; Receptor, TIE-2; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factors

2007

Trials

4 trial(s) available for pyrroles and Myelodysplastic Syndromes

ArticleYear
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.
    Clinical lymphoma, myeloma & leukemia, 2022, Volume: 22, Issue:7

    Topics: Acetonitriles; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Hematologic Neoplasms; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Pyrimidines; Pyrroles

2022
Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:11

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Indoles; Kaplan-Meier Estimate; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Pyrroles; Remission Induction; Sunitinib; Thrombocytopenia; Treatment Outcome

2014
A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:6

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Myelodysplastic Syndromes; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Thrombocytopenia; Treatment Outcome

2014
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
    Blood, 2003, Aug-01, Volume: 102, Issue:3

    Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Bone Marrow Examination; Humans; Indoles; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Necrosis; Pharmacokinetics; Protein-Tyrosine Kinases; Pyrroles; Remission Induction; Salvage Therapy

2003